23 May 2013
Keywords: uk, nice, recommends, first-line, use, novartis, glivec
Article | 08 September 2003
The National Institute for Clinical Excellence has recommended that Novartis' Glivec (imatinib) be used as a first-line treatment for people
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 September 2003
© 2013 thepharmaletter.com